(±)-Sulfinpyrazone , ≥96% , 57-96-5
Synonym(s):
(±)-Sulfinpyrazone;1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione;Diphenylpyrazone
CAS NO.：57-96-5
Empirical Formula: C23H20N2O3S
Molecular Weight: 404.48
MDL number: MFCD00057279
EINECS: 200-357-4
| Pack Size | Price | Stock | Quantity |
| 1G | RMB23.20 | In Stock |
|
| 5G | RMB43.20 | In Stock |
|
| 25G | RMB158.40 | In Stock |
|
| 100g | RMB479.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 136-137° |
| Boiling point: | 590.8±42.0 °C(Predicted) |
| Density | 1.1890 (rough estimate) |
| refractive index | 1.6360 (estimate) |
| storage temp. | Sealed in dry,Room Temperature |
| solubility | Very slightly soluble in water, sparingly soluble in ethanol (96 per cent). It dissolves in dilute solutions of alkali hydroxides. |
| form | Solid |
| pka | pKa 2.8(H2O
t = RT
I undefined) (Uncertain) |
| color | Off-White to Light Brown |
| Water Solubility | 2.601g/L(22 ºC) |
| CAS DataBase Reference | 57-96-5(CAS DataBase Reference) |
| NIST Chemistry Reference | Sulfinpyrazone(57-96-5) |
Description and Uses
Sulfinpyrazone is soluble in alkaline solutions. Its synthesis is similar to that of phenylbutazone (Fig. 36.33). It produces its uricosuric effect in a manner similar to that of probenecid. A dose of 35 mg produces a uricosuric effect equivalent to that produced by 100 mg of probenecid, whereas 400 mg/day of sulfinpyrazone produces an effect comparable to that obtained with doses of 1.5 to 2 g of probenecid. It also possesses, not surprisingly, some of the properties of phenylbutazone. It is an inhibitor of human platelet prostaglandin synthesis at the cyclooxygenase step, resulting in a decrease in platelet release and a reduction in platelet aggregation. This antiplatelet effect suggests a role for sulfinpyrazone in reducing the incidence of sudden death, which can occur in the first year following a myocardial infarction; however, it lacks the analgetic and anti-inflammatory effects of phenylbutazone.
Sulfinpyrazone is used in the treatment of gout acting as a uricosuric medication.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264-P270-P301+P312-P501 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| Safety Statements | 36 |
| WGK Germany | 3 |
| RTECS | UQ8575000 |
| HS Code | 2933194350 |
| Hazardous Substances Data | 57-96-5(Hazardous Substances Data) |
